478 POSTER Human cancer cells are sensitized to voreloxin (formerly SNS-595) after modulation of DNA double strand break repairRobert Kimmel, Joshua S. Silverman, John Kumer et al.|European Journal of Cancer Supplements|2008Cited by 0
A Phase 1/2 first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of UX053 in patients with glycogen storage disease type IIIDavid Rodriguez‐Buritica, Andrew Grimm, H. Phan et al.|Molecular Genetics and Metabolism|2024Cited by 0